Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma

被引：25

作者：

Nikiforow, Sarah ^{[1
,2
]}

Werner, Lillian ^{[3
]}

Murad, Joana ^{[4
]}

Jacobs, Matthew ^{[5
]}

Johnston, Lauren ^{[5
]}

Patches, Sarah ^{[5
]}

White, Randie ^{[5
]}

Daley, Heather ^{[5
]}

Negre, Helene ^{[5
]}

Reder, Jake ^{[4
]}

Sentman, Charles ^{[6
]}

Wade, Terri ^{[4
]}

Schmucker, Adam ^{[4
]}

Lehmann, Frederic Francois ^{[7
]}

Snykers, Sarah ^{[7
]}

Allen, Rachel ^{[7
]}

Dipietro, Heidi ^{[1
]}

Cummings, Kristen ^{[1
]}

Galinsky, Ilene ^{[1
]}

Munshi, Nikhil C. ^{[1
,2
]}

Schlossman, Robert L. ^{[2
]}

Stone, Richard M. ^{[1
,2
]}

Neuberg, Donna S. ^{[3
]}

Soiffer, Robert J. ^{[1
,2
]}

Dranoff, Glenn ^{[1
,2
]}

Ritz, Jerome ^{[1
,2
]}

Baumeister, Susanne H. C. ^{[8
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[2] Harvard Med Sch, Boston, MA USA

[3] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA USA

[4] Celdara Med LLC, Lebanon, NH USA

[5] Dana Farber Canc Inst, Boston, MA USA

[6] Geisel Sch Med, Dartmouth, NS, Canada

[7] Celyad, Celyad, SA, Australia

[8] Boston Childrens Hosp, Boston, MA USA

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.4052.4052

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4052

引用

页数：5

共 50 条

[31] Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
Ghobadi, Armin
Bachanova, Veronika
Patel, Krish
Park, Jae H.
Flinn, Ian
Riedell, Peter A.
Bachier, Carlos
Diefenbach, Catherine S.
Wong, Carol
Bickers, Cara
Wong, Lilly
Patel, Deepa
Goodridge, Jode
Denholt, Matthew
Valamehr, Bahram
Elstrom, Rebecca L.
Strati, Paolo
LANCET, 2025, 405 (10473): : 127 - 136
[32] Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma
Jie, Jin
Hao, Siguo
Jiang, Songfu
Li, Zonghai
Yang, Min
Zhang, Wenhao
Yu, Kang
Xiao, Jun
Meng, Haitao
Ma, Liyuan
He, Mingxia
Wang, Wei
Huang, Xin
Chen, Linjun
Xing, Chongyun
Yuan, Daijing
Wang, Shasha
Tao, Rong
Dai, Lihui
Ma, Hong
BLOOD, 2019, 134
[33] A phase I trial to evaluate allogeneic NKG2DL-targeting chimeric antigen receptor-grafted γ δ T cells in subjects with advanced solid tumors or hematological malignancies (the ANGELICA Trial)
Choo, Joan
Tan, Wee Kiat
Luk, Lucas
Zeng, Jieming
Soh, Teck Guan
Soon, Sou Yen
Lieow, Jedidah
Wong, Calista
Pang, Mei Yan
Bari, Sudipto
Poon, Michelle
Koh, Liang Piu
Chng, Wee Joo
Jeyasekharan, Anand
Tan, Lip Kun
Chan, Esther
Sundar, Raghav
CANCER RESEARCH, 2024, 84 (07)
[34] Engaging the NKG2D receptor with a novel bispecific protein (ULBP2-antiCD138) activates NK cells and has potent antitumor activity against human multiple myeloma.
von Strandmann, EP
Hallek, M
Engert, A
BLOOD, 2005, 106 (11) : 372B - 372B
[35] Preclinical rationale for a first-in-human trial to evaluate the safety and preliminary efficacy of desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) for mucosal pemphigus vulgaris
Payne, A. S.
Lee, J.
Lundgren, D. K.
Mao, X.
Manfredo-Vieira, S.
Nunez-Cruz, S.
Williams, E. F.
Assenmacher, C.
Radaelli, E.
Wang, B.
Ellebrecht, C. T.
Fraietta, J. A.
Milone, M. C.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S77 - S77
[36] A first-in-human clinical trial of adoptive therapy using CD19-specific chimeric antigen receptor re-directed T-cells for recurrent/refractory follicular lymphoma
Jensen, Michael. C.
Popplewell, Leslie
DiGiusto, David
Kalos, Michael
Raubitschek, Andrew
Forman, Stephen J.
BLOOD, 2007, 110 (11) : 92A - 92A
[37] Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase II Trial
Xia, Jieyun
Li, Hujun
Yan, Zhiling
Zhou, Dian
Wang, Ying
Qi, Yuekun
Cao, Jiang
Li, Depeng
Cheng, Hai
Sang, Wei
Zhu, Feng
Sun, Haiying
Chen, Wei
Qi, Kunming
Yan, Dongmei
Qiu, Tingting
Qiao, Jianlin
Yao, Ruosi
Liu, Yang
Wang, Xue
Zhang, Yanlei
Peng, Shuixiu
Huang, Chih-Hua
Zheng, Junnian
Li, Zhenyu
Chang, Alex H. H.
Xu, Kailin
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2583 - +
[38] CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered NK Cells and T Cells Enhance In Vitro and In Vivo Anti-Tumor Activity Against Human Multiple Myeloma
Chu, Jianhong
Deng, Youcai
Benson, Don M., Jr.
He, Shun
Hughes, Tiffany L.
Zhang, Jianying
Peng, Yong
Mao, Hsiaoyin
Yi, Ling
He, Xiaoming
Devine, Steven M.
Zhang, Xiaoliu
Caligiuri, Michael A.
Hofmeister, Craig C.
Yu, Jianhua
BLOOD, 2013, 122 (21)
[39] SAFETY AND MANAGEMENT OF ADVERSE EVENTS WITH CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL RESULTS FROM CARTITUDE-1
Florendo, Erika
Wilmoth, Jenai
Romanov, Vadim
Garrett, Ahsraf
Martin, Thomas
Madduri, Deepu
ONCOLOGY NURSING FORUM, 2021, 48 (02)
[40] STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors
Pinto, Navin
Albert, Catherine M.
Taylor, Mallory R.
Ullom, Heidi B.
Wilson, Ashley L.
Huang, Wenjun
Wendler, Jason
Pattabhi, Sowmya
Seidel, Kristy
Brown, Christopher
Gustafson, Joshua A.
Rawlings-Rhea, Stephanie D.
Cheeney, Safia H. E.
Burleigh, Katelyn
Gustafson, Heather H.
Orentas, Rimas J.
Vitanza, Nicholas A.
Gardner, Rebecca A.
Jensen, Michael C.
Park, Julie R.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (35)

← 1 2 3 4 5 →